Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cholesterol drug shows promise in indian patients

NCT ID NCT06386419

First seen Apr 25, 2026 · Last updated May 17, 2026 · Updated 8 times

Summary

This study looked at how safe and effective the drug inclisiran is for Indian adults with high cholesterol or mixed dyslipidemia. Sixty-five participants received the drug as a shot under the skin. Researchers tracked side effects and measured how much LDL (bad) cholesterol dropped over 300 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Novartis Investigative Site

    Bangalore, Karnataka, 560099, India

  • Novartis Investigative Site

    Belagavi, Karnataka, 590010, India

  • Novartis Investigative Site

    Mumbai, Maharashtra, 400012, India

  • Novartis Investigative Site

    Nagpur, Maharashtra, 441108, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110029, India

  • Novartis Investigative Site

    Jaipur, Rajasthan, 302039, India

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625107, India

  • Novartis Investigative Site

    Vellore, Tamil Nadu, 632 004, India

  • Novartis Investigative Site

    Kolkata, West Bengal, 700 020, India

Conditions

Explore the condition pages connected to this study.